Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain in green
Wed, 22 May 11:30 am

Indian share markets have continued on a firm note during the previous two hours of trade. IT and healthcare are leading the pack of winners while realty and auto are facing the maximum selling pressures.

The BSE-Sensex is up by 68 points and NSE-Nifty is up by 17 points. BSE Mid Cap index is trading up by 0.3% while BSE Small Cap index is trading up by 0.2%. The rupee is trading at 55.44 to the US dollar.

Indian Pharma shares are trading on a mixed note with Dr. Reddy's and Sun Pharma leading the gains while Divis Laboratories and Wockhardt Ltd are leading the losses. According to a leading financial news daily, the Health Mininstry in India has decided to initiate a probe on Ranbaxy Laboratories following the company's legal trouble in the US. The Drugs Controller General of India (DCGI) has been ordered to examine all the dossiers and drug applications on the basis of which approvals were granted to Ranbaxy in the past, a ministry source in know of the developments said. The future course of action would be decided after DCGI's report, expected to come within a month. All the officials spoken to said Ranbaxy could face severe penalties under the Drugs and Cosmetics Act if it was found guilty of violation of any provision under Indian law. According to the health ministry source, the drug regulator will initially study the US court's order and the report of the US Food and Drug Administration (FDA) and examine the period under their review, primarily pre-2005 in the Indian context. Ranbaxy's share is trading down by 1.5%.

Auto shares are trading on a mixed note with Maharashtra Scooters and Tata Motors leading the gains while TVS Motors and Force Motors are leading the losses. According to a leading financial news medium, the country's largest car maker - Maruti Suzuki's Swift Dzire has emerged as the second-highest sold car in India after Alto. The entity has sold 19,446 units of the compact sedan in April. With the increase in demand for compact sedans, the company hopes that Dzire will maintain its speed in the days ahead. Dzire sales have increased dramatically after the company went for a full model revamp last year and launched a new sub-four-metre model in February. The smaller size has allowed Dzire to halve its tax outgo, making it eligible for a lower tax bracket of 12%, and consequently passing on the benefit to customers. Maruti's share is trading up by 0.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.